Pfizer Vaccine Priced Around 20,000 Won in the US... EU Secures Cheaper Deal

EU Signs Supply Contract at Under $19.5 per Dose

[Image source=Reuters Yonhap News]

[Asia Economy Reporter Kwon Jae-hee] The European Union (EU) has agreed to procure the novel coronavirus disease (COVID-19) vaccine developed by the American pharmaceutical company Pfizer and the German biotech firm BioNTech, which showed over 90% efficacy in clinical trials, at a price lower than the supply price in the United States, major foreign media reported on the 11th (local time).

According to reports, EU officials signed a vaccine supply contract with Pfizer and BioNTech on the same day for up to 300 million doses. It was disclosed that the price was agreed to be lower than the $19.5 per dose (approximately 22,000 KRW) that the United States agreed to pay.

However, they mentioned that the exact supply price could not be disclosed.

The reason the EU is able to supply the vaccine at a lower price than the U.S. appears to be due to the European Investment Bank (EIB) and the German government providing BioNTech with 475 million euros (approximately 623.1 billion KRW) in funding for vaccine research and development.

In July, the United States signed a contract with Pfizer and BioNTech to supply 100 million doses of the COVID-19 vaccine at $19.5 per dose.

Meanwhile, the EU has also signed COVID-19 vaccine supply contracts with AstraZeneca, Sanofi, and Johnson & Johnson.

This content was produced with the assistance of AI translation services.